Artificial Heart Pioneer Doing Well After Two Months

Tuesday, 18 Feb 2014 04:45 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
A patient with terminal heart failure is in "satisfactory condition" two months after becoming the first person to be fitted with Carmat's artificial heart which is designed to beat for several years, his hospital said.
 
The 76-year-old man is eating normally, no longer needs constant respiratory assistance and is able to walk a little farther every day thanks to physical therapy, the Georges Pompidou European Hospital in Paris said in a statement on Tuesday.

"The Carmat bioprosthesis continues to function satisfactorily, without any anti-clotting treatment since January 10," said the hospital, where the implant surgery was performed on December 18 and where the patient is being treated.

It praised the patient's "exemplary courage, sense of humour and family support" for playing a role in his recovery.

Heart-assistance devices have been used for decades as a temporary solution for patients awaiting transplants, but Carmat's product is designed to replace the real heart over the long term, mimicking nature using biological materials and sensors.

It aims to extend life for thousands of patients who die each year while awaiting a donor, while reducing the side-effects that can be associated with transplants, such as blood clots and rejection.

Three more patients in France are due to be fitted with Carmat's device. The people selected in this first series of clinical studies suffer from terminal heart failure - when the sick heart can no longer pump enough blood to sustain the body - and would otherwise have only a few days or weeks to live.

Success will be judged on whether the patients survive with the implant for at least a month. If deemed safe, the device will then be fitted into about 20 lower-risk patients.

A spokeswoman for Carmat declined to say when the other three patients in the first round of tests would be fitted with its artificial heart.

The company estimates around 100,000 patients in the United States and Europe could benefit from its artificial heart.

Chief Executive Marcello Conviti told Reuters in November that Carmat hoped to finish human trials of the heart by the end of 2014 and to obtain approval to market them in the European Union by early 2015.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Mom's Depression Linked to Delinquent Kids

Monday, 22 Dec 2014 08:23 AM

Teens are more likely to smoke, drink and use marijuana -- and to doso at an earlier age -- if their mothers were depres . . .

FDA OKs First New Flu Treatment in 15 Years

Monday, 22 Dec 2014 08:19 AM

The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals' intravenous flu drug, sending the company's sha . . .

Activity Trackers Get Smarter

Monday, 22 Dec 2014 08:11 AM

Fitness activity trackers have come a long way since Leonardo da Vinci sketched a rudimentary gear-and-pendulum pedomete . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved